Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292586 · ClinicalTrials.gov registry record · Phase 3
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
A Phase 3 study of Asthma, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,377
- Enrollment target
- 20
- Study locations
NCT05292586: Completed Phase 3 study of Asthma, sponsored by Chiesi Farmaceutici S.p.A..
NCT05292586 is a Phase 3 study of Asthma that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 1,377 participants, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05292586, a Phase 3 study of Asthma, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,377 participants
- Enrollment target
- 20
- Study locations
Study Summary
Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.
Primary Outcome
The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[Visit 2\]) and the FEV1 AUC0-12h normalised by time at Week 12 (Visit 5) are presented by treatment group in the ITT population, as change from baseline. AUC0=12h Area under the curve calculated between time 0 and 12 hours
Conditions Studied
Interventions
- DRUG Beclomethasone Dipropionate/Formoterol Fumarate
- DRUG Beclomethasone Dipropionate
Study Locations (20)
California
- Chiesi Clinical Trial Site 840856 - Encinitas
- Chiesi Clinical Trial Site 840843 - Huntington Beach
- Chiesi Clinical Trial Site 840860 - Huntington Beach
- Chiesi Clinical Trial Site 840896 - Long Beach
- Chiesi Clinical Trial Site 840883 - Los Angeles
- Chiesi Clinical Trial Site 840810 - Los Angeles
- Chiesi Clinical Trial Site 840869 - Newport Beach
- Chiesi Clinical Trial Site 840890 - North Hollywood
- Chiesi Clinical Trial Site 840808 - Northridge
- Chiesi Clinical Trial Site 840879 - Pomona
- Chiesi Clinical Trial Site 840868 - Sacramento
- Chiesi Clinical Trial Site 840849 - San Diego
- Chiesi Clinical Trial Site 840877 - San Diego
- Chiesi Clinical Trial Site 840861 - San Jose
- Chiesi Clinical Trial Site 840881 - Westminster
Colorado
- Chiesi Clinical Trial Site 840873 - Colorado Springs
- Chiesi Clinical Trial Site 840800 - Denver
Alabama
- Chiesi Clinical Trial Site 840858 - Mobile
Arizona
- Chiesi Clinical Trial Site 840895 - Chandler
Florida
- Chiesi Clinical Trial Site 840820 - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,377 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 3 |
What the finished NCT05292586 record still lists
NCT05292586 is an interventional study that assigns participants to a tested intervention. Its 1,377 participants enrollment target places it among the larger protocols in the corpus, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Beclomethasone Dipropionate/Formoterol Fumarate is the first listed.
NCT05292586 names 20 study sites across 5 states, led by California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT05292586 about?
NCT05292586 is a clinical study titled "A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid". Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.
What is the current status of trial NCT05292586?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,377 participants. The study started on 2022-08-31. Estimated completion is 2024-06-24.
What conditions does trial NCT05292586 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT05292586?
The interventions under investigation include: Beclomethasone Dipropionate/Formoterol Fumarate (DRUG), Beclomethasone Dipropionate (DRUG).
Who is sponsoring clinical trial NCT05292586?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05292586 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05292586's enrollment target sits among peer trials
1,377 28th of 374 higher than 347 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI